These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 39387560)
21. Mitochondrial RNA modification-based signature to predict prognosis of lower grade glioma: a multi-omics exploration and verification study. Zhou X; Ling Y; Cui J; Wang X; Long N; Teng W; Liu J; Xiang X; Yang H; Chu L Sci Rep; 2024 Jun; 14(1):12602. PubMed ID: 38824202 [TBL] [Abstract][Full Text] [Related]
22. Machine learning identification of cuproptosis and necroptosis-associated molecular subtypes to aid in prognosis assessment and immunotherapy response prediction in low-grade glioma. Miao Y; Liu J; Liu X; Yuan Q; Li H; Zhang Y; Zhan Y; Feng X Front Genet; 2022; 13():951239. PubMed ID: 36186436 [TBL] [Abstract][Full Text] [Related]
23. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma. Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q Front Immunol; 2022; 13():1011757. PubMed ID: 36325335 [TBL] [Abstract][Full Text] [Related]
24. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma. Ma W; Mei P World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196 [TBL] [Abstract][Full Text] [Related]
25. Profiling hypoxia signaling reveals a lncRNA signature contributing to immunosuppression in high-grade glioma. Li X; Xu J; Li X; Shi J; Wei C; Liang Q Front Immunol; 2024; 15():1471388. PubMed ID: 39416790 [TBL] [Abstract][Full Text] [Related]
26. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference. Zhang C; Li J; Wang H; Song SW Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332 [TBL] [Abstract][Full Text] [Related]
27. FAM109B plays a tumorigenic role in low-grade gliomas and is associated with tumor-associated macrophages (TAMs). Zhang Z; Xiao Y; Zhao S; Liu J; Zeng J; Xiao F; Liao B; Shan X; Zhu H; Guo H J Transl Med; 2024 Sep; 22(1):833. PubMed ID: 39256832 [TBL] [Abstract][Full Text] [Related]
28. Classification of diffuse lower-grade glioma based on immunological profiling. Wu F; Wang ZL; Wang KY; Li GZ; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Zhao Z; Zhang W Mol Oncol; 2020 Sep; 14(9):2081-2095. PubMed ID: 32392361 [TBL] [Abstract][Full Text] [Related]
29. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma. Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355 [TBL] [Abstract][Full Text] [Related]
30. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma. Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903 [TBL] [Abstract][Full Text] [Related]
31. Prognostic relevance and validation of ARPC1A in the progression of low-grade glioma. Dai J; Gao J; Dong H Aging (Albany NY); 2024 Jun; 16(14):11162-11184. PubMed ID: 39012280 [TBL] [Abstract][Full Text] [Related]
32. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas. Zhao WJ; Ou GY; Lin WW Front Immunol; 2021; 12():682415. PubMed ID: 34054873 [TBL] [Abstract][Full Text] [Related]
33. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
34. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas. Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L Front Immunol; 2020; 11():603341. PubMed ID: 33363544 [TBL] [Abstract][Full Text] [Related]
35. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas. Chen J; Li Y; Han X; Pan Y; Qian X Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634 [TBL] [Abstract][Full Text] [Related]
36. Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma. Zhu W; Chen Z; Fu M; Li Q; Chen X; Li X; Luo N; Tang W; Yang F; Zhang Y; Zhang Y; Peng X; Hu G Apoptosis; 2024 Feb; 29(1-2):169-190. PubMed ID: 37713112 [TBL] [Abstract][Full Text] [Related]
37. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma. Liu Z; Cheng X; Pang B; Wang S; Liu B; Cao C; Qian R; Liang W; Zhu Y; Li P; Gao Y Int Immunopharmacol; 2022 Mar; 104():108399. PubMed ID: 35008004 [TBL] [Abstract][Full Text] [Related]
38. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas. Li Y; Feng Y; Luo F; Peng G; Li Y Front Immunol; 2022; 13():1089792. PubMed ID: 36726969 [TBL] [Abstract][Full Text] [Related]
39. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma. Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778 [No Abstract] [Full Text] [Related]
40. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients. Hu Y; Tu Z; Lei K; Huang K; Zhu X Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]